Overview

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma

Status:
Suspended
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
This phase I trial evaluates the feasibility of using hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing patients with primary central nervous system lymphoma. This trial aims to see whether MRI using hyperpolarized carbon-13 pyruvate is safe and useful for detecting central nervous system lymphoma and evaluating response to treatment.
Phase:
Phase 1
Details
Lead Sponsor:
James Rubenstein
Collaborator:
National Cancer Institute (NCI)